Health Press Release – Weekly Newsletter for December 1-6, 2010

MarketsandMarkets: U.S Digestive Health Ingredients Market Worth $495.3 Million in 2015

DALLAS, November 29, 2010 – DIGESTIVE HEALTH INGREDIENTS MARKET -U.S. analyzes the trends prevailing
in the digestive health ingredients market (
www.marketsandmarkets.com/Market-Reports/digestive-health-225.html) in
the United States. It gives the revenue forecast, competitive structure and
market share details for major segments such as digestive prebiotics,
digestive probiotics and digestive enzymes. It analyzes the product and
application trend for the major product …. Source article  : MarketsandMarkets: U.S Digestive Health Ingredients Market Worth $495.3 Million in 2015.

New SmartVascular Software Optimizes Imaging in Vascular Surgery

Software Solution From Ziehm Imaging Optimizes Mobile Imaging Workflow and Delivers Results in Just a few Steps

NUREMBERG, Germany, November 29, 2010 – Ziehm Imaging's intuitive SmartVascular software considerably simplifies
imaging in vascular surgery. It introduces an entirely new workflow for fast
results. This solution raises efficiency levels, eliminates interim C-arm
operating steps and automates the imaging processes. … Original source on Gaea Times at : New SmartVascular Software Optimizes Imaging in Vascular Surgery.

Global Dental Implants Market (2010-2015) Now Available – Sandler Research

Sandler Research announces it will carry Global Dental Implants Market (2010 -2015) Research Report in its store.

DALLAS, November 29, 2010 – (Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)
Dental implants …. Source  : Global Dental Implants Market (2010-2015) Now Available – Sandler Research.

Nov 30th US Protests: ‘China, Pay Your Fair Share on Global AIDS!’

On Eve of World AIDS Day, Simultaneous Protests at China's Washington Embassy and Los Angeles Consulate Will Target China for Misuse of the Global Fund; Over Last Ten Years, World's Second-largest Economy Received Nearly $1 Billion from the Fund, but Contributed Just $16 Million

WASHINGTON, November 29, 2010 – On the eve of World AIDS …. Original source  : Nov 30th US Protests: 'China, Pay Your Fair Share on Global AIDS!'.

World to Turn (RED)(TM) to Mark World AIDS Day

Highlighting the Fight Against AIDS and the Attainable Goal of a Generation of Babies Born HIV-Free by 2015

NEW YORK, November 29, 2010 – More than 80 iconic landmarks across 13 countries will join (RED) to
promote awareness of the ongoing fight against the AIDS pandemic, by turning
red to mark World AIDS Day on 1st December. …. Read the original article  : World to Turn (RED)(TM) to Mark World AIDS Day.

IDEV Technologies Announces First U.S. Procedure With SUPERA VERITAS(TM) Transhepatic Biliary System

Commercial Launch of Stent Delivery System Planned for Early 2011
WEBSTER, Texas, November 30, 2010 – IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced the first procedure in the United States utilizing the SUPERA
VERITAS(TM) Transhepatic Biliary System, which was recently cleared to market
by the U.S. Food …. Source article on Gaea Times at  : IDEV Technologies Announces First U.S. Procedure With SUPERA VERITAS(TM) Transhepatic Biliary System.

UK’s Indoor Air is Under Attack by Parliament

SURREY, England, November 30, 2010 – The Parliamentary Office of Science and Technology (POST) reports that
poor indoor air can cause ill health and disease, and that "no single
government department has ownership of this issue." Simultaneously, Asthma UK
unveiled research that named indoor triggers that cause asthma in the first
place.

These two significant …. Source  : Gaea News Network.

Life Healthcare Upbeat After Robust Maiden Results

JOHANNESBURG, November 30, 2010 – Life Healthcare Group Holdings Limited ("Life Healthcare" or the
"Group"), a leading provider of private healthcare services in southern
Africa, today released its maiden set of annual financial results for the
year ended 30 September 2010 since listing on the JSE on 10 June.

Highlights of the results include:

… Original source on Gaea Times at : Life Healthcare Upbeat After Robust Maiden Results.

Medivation and Astellas Complete Enrollment in Phase 3 AFFIRM trial of MDV3100 in Advanced Prostate Cancer

SAN FRANCISCO and TOKYO, November 30, 2010 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced
that patient enrollment was completed on November 15, 2010 in the Phase 3
AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral
androgen receptor antagonist, in patients with advanced prostate cancer who
have previously been treated with chemotherapy.

… Read more »»».

HCL Technologies Enters Into Multi Year end-to-end IT Infrastructure Management Engagement With Purdue Pharma L.P.

NOIDA, India, November 30, 2010 – HCL Technologies Ltd. (HCL), a leading global IT services
provider, today announced that it has signed a multi year end-to-end IT
Infrastructure Management engagement with pharmaceutical company Purdue
Pharma L.P. The scope of this engagement covers management of two data
centers and all remote locations of the client in the U.S.

[..] Read the original article: here.

Gen-Probe Launches PANTHER(TM) System, Fully Automated and Integrated Molecular Testing Instrument, in Europe

System Offers Revolutionary Productivity and Flexibility for Laboratories
SAN DIEGO, November 30, 2010 – Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company's
PANTHER(TM) system, a fully automated and integrated molecular testing system
designed with the flexibility to handle a wide range of testing needs, has
been CE-marked and is available for sale in Europe.

…. Original article on Gaea Times at  : Gen-Probe Launches PANTHER(TM) System, Fully Automated and Integrated Molecular Testing Instrument, in Europe.

Bring in Group B Strep Testing for all Women to Save Money and Lives, Urges Group B Strep Support

HAYWARDS HEATH, England, December 1, 2010 – Group B Strep Support (GBSS), the charity for the UK's biggest cause of
life-threatening infection newborn babies, is urging the Government to make
sensitive testing for group B Streptococcus (GBS) available for all pregnant
women, as recent research shows this would save money as well as tiny babies'
lives.

… Original source on Gaea Times at : Bring in Group B Strep Testing for all Women to Save Money and Lives, Urges Group B Strep Support.

SEEK: PepTcell Changes Name due to New Focus and Success

LONDON, December 1, 2010 – PepTcell, a leading UK privately-owned drug-discovery group, today
announced it is changing its name to SEEK.

Gregory Stoloff, Chief Executive Officer, explains: "SEEK has
a significant number of potential blockbuster assets in different legal
entities and we wanted to give them a common identity and purpose. Announcing
a simple and …. Source article  : SEEK: PepTcell Changes Name due to New Focus and Success.

Shire Reports Positive Efficacy and Safety Results From FAST-3 Study of FIRAZYR(R) (icatibant) for Acute Attacks of Hereditary Angioedema

DUBLIN, December 1, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced topline results from FAST-3 (For
Angioedema Subcutaneous Treatment), the largest of the Phase III trials
studying the use of FIRAZYR(R) (icatibant) for treatment of acute attacks of
hereditary angioedema (HAE).

The study showed that patients receiving treatment …. Read the original article  : here.

Elsevier Launches Innovative Online Radiology Board Review Product

New Case Reviews Online Series Mimics Format of Board Exams and Offers Interactive Self-Assessment Environment for Radiology Professionals

PHILADELPHIA, December 1, 2010 – Elsevier (www.elsevier.com/), the leading publisher of scientific,
technical and medical information products and services, today announced the
availability of Case Reviews Online, an online edition of Case Reviews print
series offering radiology professionals self-assessment preparation … Read more »».

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation

More Than 21,000 Patients Enrolled in the Largest Clinical Study With a Factor Xa Inhibitor

LONDON, December 1, 2010 – Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has
successfully completed patient enrollment for its phase III ENGAGE AF-TIMI 48
clinical study of edoxaban, a direct, specific, oral Factor Xa inhibitor that
is being investigated in … Read : Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation.

Experts Emphasize That Beta-Carotene is Indispensable as a Safe Source of Vitamin A

JENA, Germany, December 1, 2010 – The intake of preformed vitamin A from animal products is not
sufficient in parts of the population in Europe, the U.S. and Asia. The
vitamin A precursor beta-carotene therefore has an important function in
providing for an adequate supply of total vitamin A, international carotenoid
experts state in a recently published consensus …. Source article on Gaea Times at  : Experts Emphasize That Beta-Carotene is Indispensable as a Safe Source of Vitamin A.

Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer’s Disease

BEERSE, Belgium, December 1, 2010 – Janssen Pharmaceutica N.V., (Janssen) today announced a research
agreement to collaborate with GE Healthcare to develop non-invasive or
minimally invasive diagnostic biosignatures to detect Alzheimer's disease
prior to the onset of clinical symptoms. Pre-symptomatic biosignatures will
allow earlier diagnosis of the disease and may enable significantly earlier
intervention in Alzheimer's disease.

… Read the original article on Gaea Times at : Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer's Disease.

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation

More Than 21,000 Patients Enrolled in the Largest Clinical Study with a Factor Xa Inhibitor

TOKYO, December 1, 2010 – Daiichi Sankyo Company, Limited (TSE: 4568), announced today
that it has successfully completed patient enrollment for its phase III
ENGAGE AF-TIMI 48 clinical study of edoxaban, a direct, specific, oral Factor
Xa inhibitor that is being investigated in … Read : Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation.

MarketsandMarkets: U.S. Biopharmaceuticals Market Worth $144 Billion by 2016

DALLAS, December 2, 2010 – BIOPHARMA analyzes the U.S. Biopharmaceuticals Market and its growth
factors, with special emphasis on the top companies in the field and their
product pipeline. The report also analyses the current trends and focus of
the U.S. biopharmaceutical market and the challenges faced by the industry.
It also provides profiles of the major companies …. Source article on Gaea Times at  : MarketsandMarkets: U.S. Biopharmaceuticals Market Worth $144 Billion by 2016.

SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)

First Targeted Therapy Approved for the Treatment of Pancreatic NET in Europe

NEW YORK, December 2, 2010 – Pfizer Inc. (NYSE: PFE) announced today that the European Commission has
approved SUTENT(R) (sunitinib malate) for the treatment of unresectable or
metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with
disease progression in adults. Experience with SUTENT as initial treatment is
limited in … Read the original article on Gaea Times at : SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET).

Nordion Signs Letter of Intent to Divest MDS Nordion S.A.

Best Medical International Inc. Prospective Buyer of Nordion Belgium Operations

OTTAWA, December 2, 2010 – Nordion Inc. (TSX: NDN; NYSE: NDZ), a leading provider of products and
services to the global health science market, today announced it has signed a
non-binding letter of agreement with Best Medical International Inc. for the
divestiture of MDS Nordion S.A.
…. Original source  : Nordion Signs Letter of Intent to Divest MDS Nordion S.A..

TFI Extends Pharma Team After New Account Wins

LONDON, December 2, 2010 – TFI Group, one of the UK's leading event management agencies, has seen
its pharmaceutical division grow following a number of high-profile account
wins.

The account wins are the Japanese pharmaceutical company Daiichi Sankyo
Europe, to handle their portfolio of events across Europe, and an
international biotechnology company.
… Read more : TFI Extends Pharma Team After New Account Wins.

Data on Over 50,000 UK Adults Shows Fresh, Raw Nuts and Seeds Help With Energy Levels and Overall Health

Need More Energy? Break out the Nutcracker This Christmas
LONDON, December 2, 2010 – Online nutrition profiling firm MyNutrition.co.uk has identified that
fresh, raw nuts and seeds have a significant association with high energy
levels in adults. This is good news during the festive season since fresh
nuts are easy to obtain.

MyNutrition.co.uk looked at … Read more >>.

BMEYE and PULSION Sign Licensing Agreement

BMEYE's Breakthrough Totally Noninvasive Blood Pressure and Cardiac Output Technology Will be Incorporated Into PULSION's Next Generation Patient Monitors

AMSTERDAM, December 2, 2010 – BMEYE B.V., the innovators of a totally noninvasive combined beat-to-beat
blood pressure and cardiac output monitoring system, and PULSION Medical
Systems AG, a leading specialist in minimally invasive critical care and
cardiovascular patient monitoring, …. Source  : Gaea News Network.

New Report Indicates VERILAST(TM) Technology From Smith & Nephew Orthopaedics has Lowest Revision Rate Among all Hip Replacement Materials

Database tracking more than 150,000 hip implants shows ceramicized metal devices achieve highest survivorship rate five years after surgery

MEMPHIS, Tennessee, December 2, 2010 – A newly released patient registry reports that hip replacement implants
made from ceramicized metal heads which articulate against polyethylene lined
cups have been shown to have superior survivorship compared to implants made
from … Read this article on Gaea Times at : New Report Indicates VERILAST(TM) Technology From Smith & Nephew Orthopaedics has Lowest Revision Rate Among all Hip Replacement Materials.

The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas

LONDON, December 2, 2010 – The Harley Medical Group is reporting a 35% surge in patients booking in
for surgical procedures YOY as an early present for themselves, the month
before Christmas.

Many patients are taking extended Christmas holidays to ensure a full
recovery is made before they return to work in the New …. Source article  : The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas.

‘Include Veterinary Care in Christmas Plans,’ Advises the Royal College of Veterinary Surgeons

LONDON, December 3, 2010 – If you own a pet, remember to check your vet's opening hours in the run
up to Christmas, advises the Royal College of Veterinary Surgeons (RCVS), the
regulatory body for veterinary surgeons. In particular, pet owners should
make sure they know what the arrangements are for emergencies when the
practice is closed.

… Read the original article on Gaea Times at : 'Include Veterinary Care in Christmas Plans,' Advises the Royal College of Veterinary Surgeons.

INTUNIV(TM) – Shire Files Suit Against Impax and Watson

DUBLIN and PHILADELPHIA, December 3, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that its subsidiary Shire LLC has filed
a lawsuit in the U.S. District Court for the Northern District of California
against Impax Laboratories, Inc. ("Impax") and Watson Pharmaceuticals, Inc.,
Watson Laboratories, Inc.-Florida, Watson Pharma, Inc and ANDA, Inc.
(collectively "Watson") … Read this article on Gaea Times at : INTUNIV(TM) – Shire Files Suit Against Impax and Watson.